Sorrento Therapeutics is a publicly owned, anti-body centric, clinical stage biopharmaceutical company based in San Diego, California. It develops new treatments for cancer, inflammation, and autoimmune disease. The company aims to turn malignant cancers into manageable and possibly curable disease.
Sorrento's immuno-oncology (I-O) portfolio comprises of a wide array of assets, including a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody drug conjugates (ADC), and an oncolytic virus (Seprehvir).
Under the I-O category, the company's cross-portfolio asset combination therapies include:
- CD38 CAR-T -- IND enabling for multiple myeloma
- CEA CAR-T -- Phase 1 clinical trials for metastatic liver tumors
- CD38 ADC -- IND enabling
Seprehvir is also under the I-O program and is in the Phase 1 of clinical trials for solid tumors, including glioblastoma, mesothelioma, melanoma, head and neck cancer, pediatric sarcomas, and pediatric neuroblastomas.
Within the pain management category, Sorrento's ZTlido is a lidocaine topical system which is available in the market as of October 2018. They are also developing RTX (resiniferatoxin), a first-class (TRPV1 agonist) non-opioid pain management molecule. As of December 2018, several administration routs are in various stages of Phase 1 trials for terminal cancer pain as well as moderate to severe osteoarthritis pain.
VP of Corporate Development & President Ark Animal Health
VP of Sales and Business Development
Deborah H. Telman
Senior VP & General Counsel
Dr. Gunnar F. Kaufmann
Senior VP of Immunotherapy & Head of Research and Global Partnerships
Dr. Henry Ji
Chairman, President, & CEO
Dr. Hui Li
VP of Business Development and GM of China Operations
Jerome B. Zeldis
Chief Medical Officer & President of Clinical Research, Medical Affairs and Regulatory
Executive VP & CFO
Mark R. Brunswick
VP of Regulatory Affairs and Quality
Richard B. Alman
VP of Clinical Research
Stephen L. Klincewicz
VP of Parmacovigilance and Clinical Operations
Documentaries, videos and podcasts
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.